Analyst Price Targets — ONC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 12:25 pm | — | Truist Financial | $411.00 | $312.19 | TheFly | BeOne Medicines price target lowered to $411 from $412 at Truist |
| March 26, 2026 8:17 pm | Kalpit Patel | Wolfe Research | $340.00 | $276.95 | TheFly | BeOne Medicines initiated with an Outperform at Wolfe Research |
| February 26, 2026 8:23 pm | Leonid Timashev | RBC Capital | $425.00 | $322.37 | StreetInsider | BeOne Medicines (ONC) PT Raised to $425 at RBC Capital |
| February 4, 2026 10:45 am | — | Barclays | $394.00 | $346.38 | TheFly | BeOne Medicines price target raised to $394 from $385 at Barclays |
| January 12, 2026 10:52 am | — | Bernstein | $414.00 | $337.89 | TheFly | BeOne Medicines upgraded to Outperform from Market Perform at Bernstein |
| January 8, 2026 12:42 pm | — | Morgan Stanley | $405.00 | $333.87 | TheFly | BeOne Medicines price target raised to $405 from $390 at Morgan Stanley |
| November 24, 2025 12:30 pm | — | Truist Financial | $400.00 | $347.72 | TheFly | BeOne Medicines initiated with a Buy at Truist |
| November 17, 2025 8:19 pm | — | Jefferies | $420.00 | $376.63 | TheFly | BeOne Medicines price target raised to $420 from $398 at Jefferies |
| October 20, 2025 1:14 pm | Sean Laaman | Morgan Stanley | $383.00 | $319.19 | TheFly | BeOne Medicines price target raised to $383 from $350 at Morgan Stanley |
| September 18, 2025 8:34 am | — | Barclays | $385.00 | $337.43 | TheFly | BeOne Medicines initiated with an Overweight at Barclays |
Latest News for ONC
BeOne Medicines (NASDAQ: ONC - Get Free Report) and PolyPid (NASDAQ: PYPD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Volatility and Risk BeOne Medicines has a beta of
Shares of Oncolytics Biotech Inc. (TSE: ONC - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded. Oncolytics Biotech Price Performance The
BeOne Medicines remains a strong buy despite a modest 2026 guidance miss, with a $410/share 12-month price target. Brukinsa's 49% YoY growth to $3.93B in 2025 and best-in-class CLL data underpin ONC's market leadership and profitability inflection. Imminent catalysts include potential FDA approvals for Sonrotoclax (BCL2 inhibitor) and BTK-CDAC (BTK degrader), both poised to drive substantial upside in 2026.
Artisan Partners Limited Partnership reduced its stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ONC) by 7.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 249,844 shares of the company's stock after selling 20,309 shares during the quarter.
The headline numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ONC.
U.S. House Trading
No House trades found for ONC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.